mk 0663 has been researched along with aspirin in 22 studies
Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (aspirin) | Trials (aspirin) | Recent Studies (post-2010) (aspirin) |
---|---|---|---|---|---|
549 | 173 | 265 | 48,947 | 6,817 | 13,778 |
Protein | Taxonomy | mk 0663 (IC50) | aspirin (IC50) |
---|---|---|---|
Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.35 | |
Integrin beta-3 | Homo sapiens (human) | 5 | |
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.8252 | |
Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 1.375 | |
Integrin alpha-IIb | Homo sapiens (human) | 5 | |
Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.271 | |
Substance-P receptor | Cavia porcellus (domestic guinea pig) | 2.4 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 2.15 | |
Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 0.3 | |
4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | 2.4 | |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.35 | |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4081 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 12 (54.55) | 29.6817 |
2010's | 10 (45.45) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Ouellet, M; Percival, MD; Riendeau, D | 1 |
Choi, YS; Kim, JA; Kim, SH | 1 |
Al-Herz, AA; Al-Qhouti, BI; Khadadah, ME; Muqim, AT; Nahar, IK; Shehab, DK; Uppal, SS | 1 |
Bolognese, JA; Cannon, CP; Curtis, SP; Laine, L | 1 |
Ahmed, I; El Gaafary, M; El Miedany, Y; Youssef, S | 1 |
Hilário, MO; Len, CA; Terreri, MT | 1 |
Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L | 1 |
Calcagnile, F; Calogiuri, G; Ferrannini, A; Muratore, L; Muratore, M; Quarta, E; Ventura, M | 1 |
Bernardi, RM; Dalmora, SL; Ferretto, RM; Fronza, M; Sangoi, MS; Wrasse, M | 1 |
Cardoso, C; Hoffken, G; Koschel, D; Leucht, V | 1 |
Ciabattoni, G; Davì, G; Dragani, A; Ferrante, E; Habib, A; Lattanzio, S; Mattoscio, D; Mucci, L; Pascale, S; Patrono, C; Petrucci, G; Ranelletti, FO; Recchiuti, A; Rocca, B | 1 |
Soares, J | 1 |
Becker, V; Bulut, D; Mügge, A | 1 |
Blanca, M; Blanca-López, N; Campo, P; Canto, G; Doña, I; Fernández, J; Gómez, AI; Jagemann, LR; Laguna, JJ; Rondón, C; Rosado, A; Torres, MJ | 1 |
Calvello, R; Carbone, ML; Cianciulli, A; Malerba, P; Panaro, MA; Perrone, MG; Scilimati, A; Vitale, P | 1 |
Adami, S; Gatti, D | 1 |
Kasemier, J; Meek, IL; Movig, KL; van de Laar, MA; Vonkeman, HE | 1 |
Helmchen, C; Hertel, S; Schwaninger, M | 1 |
Baglie, S; Baller, EM; Franco, GC; Gevert, MV; Lupepsa, AC; Moro, MG; Sanchez, PK; Tostes, AF | 1 |
3 review(s) available for mk 0663 and aspirin
Article | Year |
---|---|
Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors.
Topics: Adolescent; Aspirin; Celecoxib; Child; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Interactions; Etoricoxib; Fever; Humans; Hypersensitivity, Immediate; Inflammation; Leukotrienes; Meloxicam; Naproxen; Pain; Prostaglandins; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Thiazines; Thiazoles; Treatment Outcome | 2006 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Osteoarthritis; Peptic Ulcer; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Pyridines; Sulfones | 2007 |
Coxibs: a significant therapeutic opportunity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Drug Interactions; Etoricoxib; Gastrointestinal Tract; Humans; Osteoarthritis; Pain Measurement; Pyridines; Spondylitis, Ankylosing; Sulfones | 2010 |
6 trial(s) available for mk 0663 and aspirin
Article | Year |
---|---|
The use of etoricoxib in patients with bronchial asthma associated with aspirin sensitivity.
Topics: Aspirin; Asthma; Cyclooxygenase Inhibitors; Drug Hypersensitivity; Etoricoxib; Humans; Pyridines; Sulfones | 2006 |
Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocation Tests; Cross Reactions; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Dyspnea; Etoricoxib; Female; Forced Expiratory Volume; Humans; Male; Peak Expiratory Flow Rate; Pyridines; Rheumatic Diseases; Single-Blind Method; Sulfones | 2006 |
Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs.
Topics: Adult; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cyclooxygenase 2 Inhibitors; Drug Hypersensitivity; Etoricoxib; Female; Humans; Male; Middle Aged; Peak Expiratory Flow Rate; Pyridines; Sulfones; Urticaria | 2007 |
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.
Topics: Adult; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Etoricoxib; Female; Humans; Immunohistochemistry; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Sulfones; Thrombocythemia, Essential; Thromboxane A2; Thromboxane B2; Thromboxanes; Treatment Outcome | 2010 |
Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs.
Topics: Acetaminophen; Adolescent; Adult; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Drug Hypersensitivity; Etoricoxib; Humans; Hypersensitivity, Immediate; Ibuprofen; Pyridines; Single-Blind Method; Sulfones; Urticaria; Young Adult | 2011 |
Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Administration Schedule; Drug Interactions; Etoricoxib; Female; Humans; Ibuprofen; Male; Meloxicam; Middle Aged; Naproxen; Netherlands; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Pyridines; Risk Assessment; Sulfones; Thiazines; Thiazoles; Time Factors; Young Adult | 2013 |
13 other study(ies) available for mk 0663 and aspirin
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
Topics: Acetylation; Animals; Aspirin; Blood Platelets; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sheep; Sulfonamides; Sulfones | 2001 |
Adverse effects of etoricoxib: other considerations.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoricoxib; Gastrointestinal Diseases; Humans; Osteoarthritis; Pyridines; Sulfones | 2005 |
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Osteoarthritis; Patient Selection; Pyridines; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Sulfones; Treatment Outcome | 2006 |
Evaluation of the changes in hemostatic parameters induced by etoricoxib in rat model.
Topics: Animals; Aspirin; Blood Coagulation Tests; Cyclooxygenase Inhibitors; Disease Models, Animal; Etoricoxib; Factor Xa; Hemostasis; Male; Prothrombin; Pyridines; Rats; Sulfones | 2008 |
Asthmatic reaction induced by Etoricoxib in a patient with aspirin-sensitive asthma.
Topics: Anaphylaxis; Aspirin; Asthma; Cyclooxygenase Inhibitors; Etoricoxib; Female; Humans; Middle Aged; Pyridines; Severity of Illness Index; Sulfones | 2008 |
Low-dose aspirin reduces gastro-protective properties of COX-2 selective inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase 2 Inhibitors; Drug Interactions; Duodenal Ulcer; Etoricoxib; Female; Humans; Middle Aged; Pantoprazole; Peptic Ulcer Hemorrhage; Pyridines; Sulfones | 2009 |
Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease.
Topics: Aspirin; Blood Platelets; Cell-Derived Microparticles; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Endothelial Cells; Endothelium, Vascular; Etoricoxib; Humans; Male; Middle Aged; Pyridines; Stem Cells; Sulfones; Vasodilation | 2011 |
Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells.
Topics: Animals; Aspirin; Celecoxib; Cell Line; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Down-Regulation; Etoricoxib; I-kappa B Proteins; Inflammation Mediators; Intramolecular Oxidoreductases; Lipopolysaccharides; Membrane Proteins; Mice; Microglia; NF-kappa B; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphorylation; Prostaglandin-E Synthases; Pyrazoles; Pyridines; RNA, Messenger; Sulfonamides; Sulfones | 2012 |
Combined toxicity of penicillin and aspirin therapy may elicit bilateral vestibulopathy.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Electronystagmography; Etoricoxib; Female; Gait Disorders, Neurologic; Humans; Male; Neurologic Examination; Penicillins; Pyridines; Reflex, Vestibulo-Ocular; Sulfones; Vestibular Diseases; Vestibular Evoked Myogenic Potentials; Vestibular Function Tests | 2013 |
Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Creatinine; Cyclooxygenase 2 Inhibitors; Etoricoxib; Gastric Mucosa; Ibuprofen; Kidney; Kidney Diseases; Male; Platelet Aggregation Inhibitors; Pyridines; Random Allocation; Rats, Wistar; Risk Factors; Stomach Diseases; Sulfones; Time Factors; Treatment Outcome | 2016 |